KRIBIOLISA™ Infliximab (REMICADE) ELISA – Total Drug

SKU: KBI1011-3 Category:

₹42,000.00

Enzyme Immunoassay for the estimation of Total (Free, Bound Or Partially Bound) Infliximab in serum and plasma.

Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%

Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Infliximab is a monoclonal antibody which has high specificity for TNF alpha, and does not neutralize TNF beta. Infliximab causes programmed cell death of TNF alpha expressing activated T lymphocytes, an important cell type mediating inflammation; hence it is generally assumed that resolution of activated T cells by Infliximab explains its efficacy in Crohns disease.

Intended Use:
For Estimation of Infliximab (REMICADE) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.

If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Species

Human
Biomarker Estimation

measures total drug (free, bound or partially bound)
Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 640 ng/ml
Detection Method

Colorimetric
Specificity

80% – 120% to Infliximab (REMICADE)
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring
Entez Gene ID

ABP 710 Human
Alternate Names / Synonyms

Infliximab, Infliximab (genetical recombination), Infliximab-abda, Infliximab-axxq, Infliximab-dyyb, Infliximab-qbtx
Alternate Drug Brand Names

Avsola, Flixabi, Inflectra, Remicade, Renflexis
Drug Bank Accession Number

DB00065
ELISA Type

Direct Sandwich Assay
Storage Temperature

Store the unopened product at 2-8 Deg C. Opened products to be stored as per temperatures indicated on the datasheet.
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer to the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products